Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Nucl Med Biol ; 40(3): 415-23, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23380519

ABSTRACT

INTRODUCTION: We report on our evaluation of the strain-promoted cyclooctyne-azide cycloaddition reaction for use in tumor pretargeting, comprising a side-by-side comparison of probes 1-3 bearing three distinct cyclooctyne moieties based respectively on the 1st and 2nd generation difluorinated cyclooctyne and the 1st generation dibenzocyclooctyne. METHODS: The probes were synthesized and labeled with (177)Lu with high yields. The probe stability and reactivity towards azides were evaluated in PBS and mouse serum, and their blood clearance, biodistribution and in vivo reactivity were evaluated in tumor-free mice. RESULTS: In serum the three probes exhibited sufficient stability for a pretargeting application with half-lives of 12-19h. In PBS, probes 2 and 3 were more reactive towards azido-conjugated Rituximab (Rtx-N3) than 1, but in contrast to 1, their reactivity decreased in mouse serum and mouse serum albumin solutions, as a result of covalent and non-covalent interactions with albumin. Biodistribution data confirmed the interactions with serum proteins in circulation: (177)Lu-1 showed a fast elimination from blood (t1/2,ß = 0.31h), while (177)Lu-2 and (177)Lu-3 were retained in blood for longer periods of time (t1/2,ß = 1.08 and 3.58h, respectively). Dual isotope biodistribution experiments assessing the reaction between (125)I-Rtx-N3 and (177)Lu-1-3 in circulation in mice showed a very limited retention of 2 and 3 in blood rich organs, indicating a minimal reactivity, while no such retention was observed for 1. CONCLUSION: The low reactivity of the studied cyclooctynes, and their serum interactions preclude their use at the low in vivo concentrations typical for pretargeting applications.


Subject(s)
Alkynes/chemistry , Click Chemistry , Alkynes/metabolism , Alkynes/pharmacokinetics , Animals , Antibodies, Monoclonal, Murine-Derived/chemistry , Antibodies, Monoclonal, Murine-Derived/therapeutic use , Azides/chemistry , Drug Stability , Female , Heterocyclic Compounds, 1-Ring/chemistry , Lutetium/therapeutic use , Mice , Radioisotopes/therapeutic use , Rituximab
2.
Bioconjug Chem ; 8(3): 257-66, 1997.
Article in English | MEDLINE | ID: mdl-9177829

ABSTRACT

Four generic heterobifunctional reagents, namely 2-(2-chloro-5-methyl-1,3,2-dioxaphosphorinan-5-yl)methoxyacetic acid methyl ester, p-sulfide, 2-(2-chloro-5-methyl-1,3,2-dioxaphosphorinan-5-yl)-methoxyacetic acid methyl ester, p-oxide, 2-(2-mercapto-5-methyl-1,3,2-dioxaphosphorinan-5-yl)-methoxyacetic acid bispotassium salt, p-sulfide-, and (2-methoxy-5-methyl-1,3,2-dioxaphosphorinan-5-yl)methoxyacetic acid, methyl ester, have been synthesized and used to prepare organophosphate, thiophosphate, and dithiophosphate haptens containing a functional carboxyl group which can be used to conjugate the haptens to proteins. These hapten-protein conjugates have been used as antigens for preparing polyclonal sera against all classes of organophosphate pesticides. The eight examples used protein-hapten conjugates of chlorpyrifos, parathion, diazinon, paraoxon, azinphos, dimethoate, demeton, and dichlorvos. These were all immunogenic and resulted in sera containing antibodies that recognized the corresponding parent pesticide with high specificity.


Subject(s)
Antibody Formation , Haptens/immunology , Insecticides/immunology , Organophosphorus Compounds , Acetates/chemical synthesis , Animals , Female , Immunoassay , Insecticides/analysis , Mice , Mice, Inbred BALB C , Mice, Inbred DBA
3.
Chirality ; 4(3): 155-62, 1992.
Article in English | MEDLINE | ID: mdl-1586586

ABSTRACT

Rac-ML-1035 (MDL 201,035: 4-amino-5-chloro-2-[2-(methylsulfinyl)ethoxy]-N-[2-(diethylamino)ethyl] benzamide hydrochloride) is a racemic gastroprokinetic with serotonergic (5-hydroxytryptamine, 5-HT) activity and a novel chiral sulfoxide substituent. Chromatographic and chemical methods have been developed to resolve the enantiomers of rac-ML-1035, and the absolute configuration of the (R)-enantiomer has been determined. We also report pharmacological characterization of rac-ML-1035 and its respective isomers. Radioligand binding to rat cortical membranes revealed that (R)-ML-1035 (MDL 201,226) and (S)-ML-1035 (MDL 201,227) had equivalent activity at the 5-HT3 receptor. However, in isolated tissue studies including field-stimulated guinea pig ileum, field-stimulated rat fundic strip, and nonstimulated guinea pig ileum, (S)-ML-1035 was equally potent yet had greater maximal activity than (R)-ML-1035 in eliciting or facilitating cholinergic contractions. Thus, enantiomers of rac-ML-1035 can be resolved, and the relative configuration of these isomers influences their pharmacological activity.


Subject(s)
Benzamides/pharmacology , Metoclopramide/analogs & derivatives , Animals , Benzamides/chemistry , Benzamides/metabolism , Guinea Pigs , Ileum/drug effects , In Vitro Techniques , Male , Muscle Contraction/drug effects , Rats , Receptors, Serotonin/metabolism , Stereoisomerism , X-Ray Diffraction
4.
Phys Rev Lett ; 65(17): 2141-2144, 1990 Oct 22.
Article in English | MEDLINE | ID: mdl-10042464
5.
Int J Appl Radiat Isot ; 36(5): 339-43, 1985 May.
Article in English | MEDLINE | ID: mdl-3874834

ABSTRACT

DL-[1-11C]Proline has been synthesized by carboxylation of alpha-lithiopyrrolidyl-N-tert-butyl-formamidine with a radiochemical yield of up to 18% without correction for decay. The total synthesis time is 45 min. Accumulation of DL-[1-11C]proline has been shown in Walker 256 carcinosarcoma transplanted in rats. A tumor/non-tumor ratio of 5.9 was found at 45 min after i.v. injection.


Subject(s)
Carbon Radioisotopes , Carcinoma 256, Walker/diagnostic imaging , Animals , Female , Isotope Labeling , Neoplasm Transplantation , Proline/metabolism , Rats , Rats, Inbred Strains , Stereoisomerism , Tomography, Emission-Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...